Edwards Lifesciences (NYSE:EW) delivered a solid first quarter when the company announced its results in March. Revenue increased by 11% year over year while earnings were up by 8%.

Did investors receive similar good news when the medical device maker reported its Q2 results after the market closed on Tuesday? Here are the highlights from Edwards' latest quarterly update.

An illuminated heart in a silhouetted body.

Image Source: Getty Images.

By the numbers

Edwards Lifesciences reported revenue for the second quarter totaling $1.1 billion. This reflected a 15% increase from the prior-year period revenue total of $943.7 million. The consensus among Wall Street analysts projected Q2 revenue of $1.04 billion.

How did Edwards Lifesciences' bottom line look in the second quarter? The company reported net income of $242.3 million, or $1.14 per share, on a generally accepted accounting principles (GAAP) basis, compared to $282.7 million, or $1.32 per share, in the same period in 2018.

The company's adjusted net income in the second quarter was $1.38 per share. This was an improvement of Edwards Lifesciences' result in the prior-year period when the company announced adjusted net income of $1.24 per share. It was also better than the consensus analysts' adjusted earnings estimate of $1.33 per share.

Behind the numbers

Sales in all product lines increased for the quarter. Transcatheter aortic valve replacement (TAVR) sales increased 16% to $678 million. Transcatheter mitral and tricuspid therapies (TMTT) sales rose to $7 million from a minimal amount in the prior-year period. Surgical structural heart and critical care jumped nearly 15% year over year to $218 million.

What fueled this growth? First, TAVR sales increased because of global procedure growth, even with its prices remaining stable. Commercial sales of the Pascal transcatheter mitral system in Europe drove overall TMTT sales growth. Surgical structural heart product sales rose due to higher demand for premium products, particularly with increased adoption of the Inspiris Resilia aortic valve.

Edwards Lifesciences' GAAP net income declined from the prior-year period. However, the decrease stemmed from higher income taxes in Q2 of 2019 compared to an income tax benefit in the same quarter of 2018.

However, the company's non-GAAP adjusted earnings looked better than its GAAP result. This was primarily because of an adjustment related to a large TAVR inventory write-off.

Looking ahead

Edwards Lifesciences expects that revenue for full-year 2019 will be between $4.0 billion and $4.3 billion, near the top end of its previous range. The company also anticipates adjusted non-GAAP EPS to be between $5.20 and $5.40. This is an increase from the previous guidance of non-GAAP EPS between $5.10 and $5.35.

Investors can be on the lookout for several milestones during the rest of the year. An important one is the expected FDA approval in the third quarter of the SAPIEN 3 valve intended for patients with low surgical risk.